A former hedge fund manager turned pharmaceutical businessman has purchased the rights to a 62-year-old drug used for treating life-threatening parasitic infections and raised the price overnight from $13.50 per tablet to $750 bringing the annual cost of treatment for some patients to hundreds of thousands of dollars.